Stereotaxis, Inc. STXS R2K
Company Overview
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Navigation by reducing the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a Synchrony and SynX Solution offer integrated, real-time information solution to manage, control, record and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including MAGiC catheter, a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures; MAGiC Sweep, a mapping catheter; QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; and V-CAS devices. Further, it provides interventional devices under the Map-iT, MAGiC, and EMAGIN brands, and other related devices. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.27.
Recent Developments
- Dec 2025 Revenue of $32.38M (+20.3% YoY); net profit $-21.64M.
- Trailing 12 Months Year-on-year growth — revenue -15.8%.
- 5-Year Trend Long-term compounding — revenue CAGR -2.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -2.82% |
| 1 Year: | -15.80% |
Stock Price Performance
| 1 Year: | -29.52% |
| 6 Months: | -36.25% |
| 3 Months: | -16.67% |
| 1 Month: | -12.09% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)36.79 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -2.8% CAGR over 5 years.
- Trading 55.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | STXS Stereotaxis, Inc. R2K | 1.60 | -6.67 | $156.38M | 0.00% | -73.98% | - | -2.82% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 6.98M | - | - | 6.97M | 7.55M | 7.56M | 7.01M | 6.80M | 8.20M | 5.76M | 5.35M | 8.70M | 8.62M | 9.05M | 9.11M | 7.04M | 6.15M | 7.66M | 6.55M | 7.86M | 7.80M | 6.88M | 4.50M | 9.20M | 7.47M | 8.80M | 7.46M | 6.29M |
| Gross Profit | 7.32M | 6.23M | 6.74M | 6.06M | 6.52M | 7.47M | 6.90M | 6.72M | 6.83M | 6.47M | 6.78M | 6.08M | 5.72M | 6.26M | 6.22M | 5.71M | 6.16M | 5.92M | 5.60M | 5.65M | 6.37M | 4.80M | 4.26M | 4.68M | 6.02M | 6.53M | 4.73M | 4.92M | 4.67M | 4.57M | 3.88M | 4.19M | 4.06M | 3.97M | 3.31M | 4.10M | 4.06M | 4.58M | 4.10M | 3.79M |
| Operating Income | -1.07M | - | -2.23M | -2.29M | -1.18M | - | -1.41M | -1.72M | -907.48K | -1.49M | -1.64M | -1.17M | -1.90M | -434.78K | 167.80K | -1.13M | -626.06K | -113.78K | -2.14M | -1.46M | -41.21K | -2.05M | -1.92M | -1.56M | -1.53M | -3.39M | -4.62M | -4.09M | -5.18M | -5.05M | -5.62M | -5.28M | -5.64M | -4.75M | -6.02M | -6.34M | -5.93M | -3.98M | -6.56M | -5.98M |
| Net Income | -56.87M | -3.96M | -4.14M | -1.94M | 22.67K | 856.22K | -3.14M | -1.54M | -996.93K | -2.27M | -2.33M | -6.21M | 1.18M | -177.30K | -4.33M | 1.44M | -632.21K | -116.30K | -2.12M | -1.43M | 43.75K | -1.97M | -1.92M | -1.57M | -1.53M | -1.21M | -4.62M | -4.09M | -5.13M | -4.92M | -5.35M | -4.96M | -5.37M | -4.51M | -5.83M | -6.19M | -5.82M | -3.83M | -6.46M | -5.86M |
| Diluted EPS | -4.49 | -0.23 | -0.21 | -0.10 | 0.00 | 0.04 | -0.15 | -0.07 | -0.05 | -0.11 | -0.11 | -0.56 | 0.01 | -0.02 | -0.21 | 0.01 | -0.02 | -0.01 | -0.04 | -0.03 | 0.00 | -0.03 | -0.03 | -0.03 | -0.02 | -0.02 | -0.07 | -0.06 | -0.07 | -0.07 | -0.07 | -0.07 | -0.07 | -0.06 | -0.07 | -0.08 | -0.07 | -0.05 | -0.07 | -0.06 |
| R&D Expense | 1.30M | - | 1.50M | 1.31M | 1.21M | - | 1.49M | 1.42M | 1.49M | 1.47M | 1.42M | 1.30M | 1.60M | 1.76M | 1.62M | 1.96M | 2.03M | 2.00M | 2.96M | 2.70M | 1.75M | 2.11M | 1.98M | 1.95M | 2.37M | 2.72M | 2.50M | 2.45M | 2.89M | 2.82M | 2.75M | 2.65M | 2.67M | 2.24M | 2.27M | 2.45M | 2.35M | 1.78M | 2.55M | 2.40M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.15M | 54.05M | 41.99M | 46.56M | 38.03M | 35.01M | 37.67M | 32.16M | 31.14M | 29.35M | 28.90M | 26.63M | 35.02M | 28.15M | 26.77M | 26.92M | 32.38M |
| Gross Profit | 34.13M | 38.49M | 29.49M | 31.78M | 27.03M | 26.79M | 27.24M | 24.63M | 20.39M | 23.63M | 22.77M | 18.97M | 23.23M | 18.47M | 14.86M | 14.59M | 17.07M |
| Operating Income | -23.84M | -18.96M | -31.94M | -10.63M | -8.84M | -5.38M | -5.41M | -6.43M | -5.92M | -2.46M | -4.83M | -6.71M | -12.89M | -18.78M | -21.84M | -24.74M | -22.11M |
| Net Income | -27.49M | -19.92M | -32.03M | -9.24M | -68.76M | -5.20M | -7.35M | -5.29M | -5.89M | 116.76K | -4.59M | -6.65M | -10.72M | -18.29M | -20.71M | -24.05M | -21.64M |
| Diluted EPS | - | -3.94 | -5.84 | -1.33 | -5.95 | -0.26 | -0.35 | -0.54 | -0.32 | -0.03 | -0.10 | -0.11 | -0.16 | -0.26 | -0.27 | -0.30 | -0.25 |
| R&D Expense | 14.26M | 12.24M | 12.89M | 8.41M | 5.67M | 5.16M | 6.25M | 5.49M | 6.70M | 8.22M | 9.02M | 8.14M | 10.20M | 10.56M | 10.27M | 9.76M | 9.38M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 65.76M | 39.93M | 32.17M | 31.08M | 23.88M | 18.88M | 20.97M | 10.67M | 18.51M | 43.58M | 55.46M | 60.98M | 53.41M | 41.91M | 46.72M | 52.25M |
| Total Equity | 4.77M | 7.64M | 10.48M | -18.83M | -18.79M | -11.70M | -12.55M | -17.63M | -21.49M | -26.57M | 1.31M | 22.77M | 34.62M | 33.84M | 26.35M | 16.34M | 6.08M | 13.48M |
| Cash & Equivalents | 30.36M | 30.55M | 35.25M | 13.95M | 7.78M | 13.78M | 7.27M | 5.59M | 8.50M | 3.69M | 10.80M | 30.18M | 43.94M | 38.74M | 8.59M | 19.82M | 12.22M | 13.42M |
| Long Term Debt | - | - | 8.00M | 17.29M | 16.82M | 18.48M | 18.39M | 18.08M | - | - | - | - | 973.25K | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | 36.43M | 36.50M | 36.50M | 31.27M | 11.24M | 15.06M | 15.23M | 21.56M | 21.48M | 19.99M | 35.29M | 33.53M |
| Current Liabilities | - | - | 46.80M | 40.83M | 33.65M | 23.80M | 16.41M | 16.14M | 35.65M | 30.13M | 10.19M | 12.16M | 13.57M | 13.26M | 14.29M | 13.25M | 21.60M | 22.36M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -22.31M | -18.91M | -31.57M | -12.12M | - | - | - | -4.67M | -2.55M | -4.62M | -3.51M | -2.95M | -8.41M | -9.14M | -8.50M | -13.69M |
| Investing Cash Flow | -1.48M | -715.77K | -1.03M | -130.70K | - | - | - | -81.58K | -265.48K | -29.49K | -70.90K | -1.40M | -22.09M | 19.77M | 74.00K | -93.00K |
| Financing Cash Flow | 23.98M | 24.33M | 11.31M | 6.07M | - | - | - | -58.95K | 9.92M | 24.03M | 17.34M | 547.00K | 220.00K | 81.00K | 297.00K | 14.76M |
| Dividends Paid | - | - | - | - | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 66.7% | 71.2% | 70.2% | 68.3% | 71.1% | 76.5% | 72.3% | 76.6% | 65.5% | 80.5% | 78.8% | 71.2% | 66.3% | 65.6% | 55.5% | 54.2% | 52.7% |
| Operating Margin % | -46.6% | -35.1% | -76.1% | -22.8% | -23.2% | -15.4% | -14.4% | -20.0% | -19.0% | -8.4% | -16.7% | -25.2% | -36.8% | -66.7% | -81.6% | -91.9% | -68.3% |
| Net Margin % | -53.8% | -36.9% | -76.3% | -19.8% | -180.8% | -14.9% | -19.5% | -16.4% | -18.9% | 0.4% | -15.9% | -25.0% | -30.6% | -65.0% | -77.4% | -89.3% | -66.8% |
| ROE % | -359.8% | -190.2% | 170.1% | 49.2% | 587.6% | 41.5% | 41.7% | 24.6% | 22.2% | 8.9% | -20.2% | -19.2% | -31.7% | -69.4% | -126.7% | -395.5% | -160.5% |
| ROCE % | - | -100.0% | 3,546.8% | 714.0% | -121.4% | -72.0% | -197.5% | 43.8% | 30.4% | -29.5% | -15.4% | -16.0% | -27.0% | -48.0% | -76.2% | -98.5% | -74.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | DAFNA Capital Management, LLC | 20.73% | 13.68M | $25.32M |
| 2 | Lagoda Investment Management, L.P. | 6.59% | 4.35M | $8.05M |
| 3 | Blackrock Inc. | 5.99% | 3.96M | $7.32M |
| 4 | Vanguard Capital Management LLC | 4.54% | 3.00M | $5.55M |
| 5 | Arbiter Partners Capital Management LLC | 4.37% | 2.88M | $5.34M |
| 6 | Geode Capital Management, LLC | 2.54% | 1.68M | $3.10M |
| 7 | Essex Investment Management Co LLC | 2.41% | 1.59M | $2.94M |
| 8 | Archon Capital Management LLC | 1.86% | 1.23M | $2.27M |
| 9 | Warberg Asset Management LLC | 1.66% | 1.09M | $2.03M |
| 10 | State Street Corporation | 1.45% | 957.77K | $1.77M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for STXS
Stereotaxis folds Robocath into its surgical robotics platform - Stock Titan
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNb3BlV0V3dFU5NXJOaXl4Z01kMnRsN2kyNnhNME43VHJHYVdhMG5LRmplcEkwVjFtY1AtNWxWVjJESjhicnRsUWg4Y2twZi01TDBJQkFkdG91UE1hVU9oYXpwdjJzOW82eHgxUHByV05OazZVQnl2UlNaR0s2Uld6aU1rM3BsR2lzNTZMNl…
STXS Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE13SW9zaFdZMXVfd0lDRFpkMlhQWXNxWHRjUTQwaHJ5Mi1uN0l1R0pPakNKM1kwLUppY3o4NnN0NnhOZzExSGxQMjhiTEFWcTZGZHc0bEZIczlzNFl5NjhleUxmV1NDMUtqNzEyQ2czUXZxSVh3VmhB?oc=5" target="_blank">STXS Fo…
Analysts See 124.7% Upside In Stereotaxis (STXS); Find Out Why - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPWEpMU1BGVEhoNDZTa2NlM0xSdFhpNDViXy1XbjN4ZE5fSERMQ1FVa05Ub0RTZnNmaEpic1RTVGhqN0NqS3c1WWNwb0hlc0xjZ3lxeEloX29qa1BaWkI3bDJPY2FSd3ZwWDdMbTRoS3RLYmJuVWstOEtXOUFzaUlEbmRpNU1Mczl5NXk3cV…
Robocath deal adds stock, warrants and earnouts at Stereotaxis (STXS) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQMkFWbVhqQVNwenBvdWNUMmZWQ0czdUo0Q1V1TUNCX21nTHEwbm8wNWVxWjYyT1huUllsQTVNMkdRRjl5cHd5bkM1NV9INHV5NFZEbTJUdWhrS2V2MHpNdEVBYkZYM25mR0VzcDNuRHhkd003dDZDTkREczctNjZWbFBWNXdkTzljdi13em…
Why Stereotaxis (STXS) Could Be One of the Best Robotics Stocks to Buy Under $30 - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNUkkxYndYQmZfRzhiYW1fWDR5UFNwbFBNeW1OTHlpSlN5V1FoQzc2V003VUVKckw5WFFpUGpzb2RzeHZnVWhDaFdfdFhtODQ1dklUMjF1c3UtZnVscVhYOXVFNEZUeDRLeTA3VGEtVHpfNlBPQ1FuNWJjU2s2MWFaWmxYaWstWVI0bUZRSG…
Stereotaxis: Medical Robotics Upside Offsets Cash Burn And Execution Risks (NYSE:STXS) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNaWh3NnVVQmRJeXNVZGVsT1dWQlAxVDhUdUZQb3JpZlBZYTd6SkE2NnVEY1d2dkZzV1oxV3Jpa1ZyS2xDTU5ZM0ZSUFFvWmM4QURBV3NadF9ZeUFid2NZUVZaOUdQcWR6dGNkR3pkaE9lSkN5T2RRR3BQbTRibEdZT2VTNXFoUDhBMlBnWT…
STXS — Frequently Asked Questions
What is the current share price of Stereotaxis, Inc. (STXS)?
As of 2026-07-14 21:23 PDT, Stereotaxis, Inc. (STXS) trades at $1.60 on NYSE American. Its 52-week range is $1.60 to $3.57.
What is the market capitalisation of STXS?
Stereotaxis, Inc. (STXS) has a market capitalisation of $156.38M on NYSE American.
What is the P/E ratio of STXS?
STXS trades at a trailing price-to-earnings (P/E) ratio of -6.67. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 13.05.
Is STXS a good stock to buy?
This page provides a data-driven analysis of Stereotaxis, Inc. (STXS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.